Evelo Biosciences

Simba Gill, CEO
Simba Gill, CEO
USA | Funding: $397M (+)

Website: http://evelobio.com/

Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.